RxDoctor Payments Data

Amee Majmundar, MD

Allergy & Immunology · Orland Park, ILNPI 1093794620

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by CSL Behring at 30.2% of the total. 2025 is the largest year on record at $6,651, more than ten times the $383 reported in 2019.

$11,596in general payments, 2019–2025

Across 227 payments — averaging $51.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$4K
  • Sanofi$2K
  • Genentech USA, Inc.$1K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$973
  • Novartis$343
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$5,58548%
  • Travel & lodging$6175%
  • Food & beverage$5,37946%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,596 in reported general payments places this provider in the 75th percentile of 161 allergy & immunology providers in Illinois.

See all allergy & immunology providers in Illinois

Medicare billing

Part B allowed, 2024
$173,684
Medicare patients
217
Services billed
8,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab19$51,911
Breo ElliptaFluticasone/Vilanterol23$13,837
DuleraMometasone/Formoterol17$6,444
Advair HfaFluticasone Propion/Salmeterol15$6,008
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,392
SymbicortBudesonide/Formoterol Fumarate14$5,365
Epinephrine17$3,173
Ipratropium Bromide95$2,542
Levocetirizine Dihydrochloride110$2,046
Montelukast Sodium93$943
Azelastine Hcl34$832
Albuterol Sulfate HfaAlbuterol Sulfate31$762
Doxepin Hcl26$540
Triamcinolone Acetonide20$138
Prednisone54$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$317$13,83723 claims
MerckDulera$36$6,44417 claims
AstraZenecaSymbicort$1,056$5,36514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 allergy & immunology providers in Illinois.

Other allergy & immunology in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →